• Forgiving with difficult cases, helping the surgeon to hit the desired refractive target. • Predictable, providing reproducible, consistent outcomes. • With a low rate of halos and glare, comparable to a monofocal. • Complementary with other multifocal lenses such as AcrySof IQ PanOptix®. • Effective with monovision. • Well tolerated in patients with mild retinal disease and glaucoma. Based on the surgeons’ panel experience, AcrySof IQ Vivity® is: Thanks to AcrySof IQ Vivity®, Dr. Sandeep Nagvekar was able to lead a challenging case to a happy ending. The patient was a 65-year old very eminent lawyer with an amblyopic eye since his early childhood due to monocular hyperopia of about +3.75D. He was an avid tennis player, and he enjoyed driving on weekends. After a life spent wearing glasses, the patient was not keen on being implanted with a monofocal, but Dr. Nagvekar was hesitant to offer him a trifocal in order to promote his passion for driving. AcrySof IQ Vivity® is a novel breakthrough option in cataract refractive surgery, a promising addition to the presbyopia-correction category of IOLs. It is an easy entry into presbyopia correction for every general cataract surgeon, with the same intermediate vision capability of multifocal lenses, but without the downside of visual symptoms. It is a suitable choice also for patients with mild vitreoretinal conditions. According to the participants’ personal experience and knowledge, AcrySof IQ Vivity® is already winning over the monofocal market, and the number of doctors switching to this lens has skyrocketed in different subspecialties. They all agreed that the innovative X-WAVE™ technology may open a brand-new generation of IOLs, an entirely new IOL category overcoming the concept of EDOF. “AcrySof IQ Vivity® could become the new standard of care, efficiently addressing a gap in the correction of presbyopia” - A/Prof. Chandra Bala, Australia “AcrySof IQ Vivity® is a lens for patients who understand the value of intermediate vision” - Dr. Abhay R. Vasavada, India “Most multifocality issues I experienced with other IOLs are all addressed and solved by AcrySof IQ Vivity®” - A/Prof. Khairidzan Mohd Kamal, Malaysia “I don’t think there should be any concern about the angle alpha unless this is really, really huge” - Dr. Lee Hung Ming, Singapore “It is a wonderfully forgiving lens, especially in case of decentration. We should classify it as a new type of lens” - Dr. Jony Chang, Taiwan “This is something that will upgrade my clinical experience. I am probably going to use more AcrySof IQ Vivity® in the future” - Dr. Fook Meng Cheong, Malaysia “Despite all the lenses we have at our disposal, Vivity® really introduces a new element into our practice. These are very exciting times we live in!” - Dr. Ronald Yeoh, Singapore Dr. Sandeep Nagvekar, Nagvekar Eye Clinic, India “In all the 12 years that I knew him, his vision with glasses, even before the cataract onset, had never been more than 20/40. It astounded me.” From amblyopia to happiness A new standard - discussion and conclusions References 1. AcrySof IQ Vivity® Extended Vision IOL Directions for Use. 2. Alcon Data on File, US Patent 9968440 B2, May 15, 2018. 3. Maxwell WA, Lane SS, Zhou F. Performance of presbyopia-correcting intraocular lenses in distance optical bench tests. J Cataract Refract Surg. 2009 Jan;35(1):166-71. doi: 10.1016/j.jcrs.2008.10.026. PMID: 19101440. 4. Kohnen T, Suryakumar R. Extended Depth-of-Focus Technology in Intraocular Lenses. J Cataract Refract Surg. 5. TECNIS Symfony® Extended Range of Vision IOL [package insert]. Santa Ana, CA: Abbott Medical Optics, Inc. 6. Schallhorn SC, et al. J Refract Surg. 2019;35(7):426-433. 7. Soda M, Yaguchi S. Ophthalmologica 2012;227:197-204. 8. Rosen E. J Cataract Refract Surg. 2016;422:310-328. 9. Alcon Data on File. TDOC-0055575. 09 Apr 2019. 10. García-Pérez JL et al. BMC Ophthalmol 2017;17:72 11. Kohnen T et al. Am J Ophthalmol 2017;184:52 12. Prof. Soon-Phaik Chee’s experience 13. Bissen-Miyajima H et al. Jpn J Ophthalmol 2020;64:140 14. Alcon Data on file. Optical Evaluations of Alcon Vivity, Symfony and Zeiss AT LARA IOLs Bench study. 15. Alcon Research LLC. AcrySof™ IQ Vivity™ product information (US version). Available at: https://ifu.alcon.com. [accessed 11 Feb 2021]. 16. Alcon Research LLC. AcrySof™ IQ Vivity™ product information (UK version). Available at: https://ifu.alcon.com. [accessed 11 Feb 2021 Eventually, he opted for an AcrySof IQ Vivity® in both eyes (Fig.4), and results were outstanding. At 3 months, the patient was 20/30 uncorrected in the right eye, intermediate vision was 20/20 binocularly and near vision was 20/32 as expected. According to Dr. Nagvekar, the patient gladly accepted an addition of +1.25 for near, and still is absolutely delighted with the results. Vivity® was a lifechanger: before the operation, his colleagues used to do most of the reading and briefing for him. Fig.4 - Vivity® implanted bilaterally in a difficult case of amblyopia Sponsored by Alcon Disclaimer: Above presented are clinical experience from respective surgeon, although preliminary clinical experiences are favorable in various scenarios but more data will be needed to confirm these in larger population. The safety and effectiveness of Vivity has not been substantiated in clinical trials in patients with certain pre-existing conditions and/ or intraoperative conditions, including uncontrolled glaucoma, amblyopia or previous refractive surgery etc, as these patients were excluded from the pivotal clinical studies.15,16 ASIA-VIV-2200001
RkJQdWJsaXNoZXIy Njk2NTg0